American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 24, Issue 1 , Pages 1-5 , January 2003

Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck

  • Avi Khafif, MD

      Affiliations

    • Department of Otolaryngology–Head and Neck Service, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
    • ,
  • Vikki A. Canfield, MD

      Affiliations

    • Department of Otolaryngology–Head and Neck, The University of Oklahoma Health and Sciences Center, Oklahoma City, OK.
    • ,
  • Elizabeth J. Syzek, MD

      Affiliations

    • Department of Otolaryngology–Head and Neck, The University of Oklahoma Health and Sciences Center, Oklahoma City, OK.
    • ,
  • Jesus E. Medina, MD

      Affiliations

    • Department of Otolaryngology–Head and Neck, The University of Oklahoma Health and Sciences Center, Oklahoma City, OK.

References 

  1. Gross WE, Lehane DE, Dixon DO, et al.  Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: A Southwest Oncology Group Study. Cancer Treat Rep. 1985;69:577–581
  2. Carter SK. The chemotherapy of head and neck cancer. Semin Oncol. 1977;4:413–424
  3. Hass CD, Coltman CA, Gottlic JA, et al.  Phase II evaluation of bleomycin: A Southwest Oncology Group Study. Cancer. 1976;38:8–12
  4. Hainsworth JD, Williams DS, Einhorn LH, et al.  Successful treatment of resistant germinal neoplasms with VP-16 abd cisplatin: Results of Southwestern Cancer Study Group trial. G Clin Oncol. 1985;3:666–671
  5. Evans WK, Shepherd FA, Feld R, et al.  VP-16 and cisplatin as first-line therapy of small cell lung cancer. J Clin Oncol. 1985;3:1471–1477
  6. Bender RA, Anderson T, Fisher RI, et al.  Activity of Epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin's lymphoma. Am J Hematol. 1987;5:203–209
  7. McElwain TJ, Selby P. Etoposide in combination for the treatment of Hodgkins disease. In:  Issell BF,  Muggia FM,  Carter SK editor. Etoposide: Current Status and New Developments. Orlando, FL: Academic Press Inc; 1984;p. 293–299
  8. Bennet JM, Lymann GH, Cassileth PA, et al.  A phase II trial of VP-16-213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 1994;7:471–473
  9. Cruellari D, Verones A, Magri MD, et al.  Phase II trial of oral VP-16-213 (etoposide) in patients with advanced head and neck cancer. Tumori. 1985;71:499–500
  10. Giocanti N, Hennequin C, Balosso J, et al.  DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res. 1993;53:2105–2111
  11. Minehan KJ, Bonner JA. The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment. Life Sci. 1993;53:237–242
  12. Cavilli F, Suntag RW, Jungi F, et al.  VP-16-213 monotherapy for remission induction of small cell lung cancer: A randomized trial using dosage schedules. Cancer Treat Rep. 1978;62:473–475
  13. Thompson DS, Hainsworth JD, Hande KR, et al.  Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I/II study. J Clin Oncol. 1993;11:1322–1328
  14. Wolff SN, Johnson DH, Hande KR, et al.  High dose VP-16-213 as single agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep. 1983;67:957–958
  15. Marcial VA, Pajak TF, Chang C, et al.  Hyperfractionation and photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys. 1987;13:41–47
  16. Harrison LB, Raben A, Pfister DG, et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in un-resectable tumors of the head and neck. H&N. 1998;20:497–503
  17. Lin JC, Jan JS, Hsu CY. Concomitant chemotherapy for advanced head and neck cancer. Jpn J Clin Oncol. 1994;24:94–100
  18. Zidan J, Kuten A, Rosenblatt E, et al.  Intensive chemotherapy using cisplatinum and fluorouracil followed by radiotherapy in advanced head and neck cancer. Oral Oncol. 1997;33:129–135
  19. Wendt TG, Grabenbauer GG, Rodel CM, et al.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998;16:1318–1324
  20. Lewin F, Damber L, Johnson H, et al.  Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: A randomized phase III study. Radiother Oncol. 1997;43:23–28
  21. Brizel DM, Albers ME, Fisher SR, et al.  Hyper-fractionated irradiation with and without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;18:1798–1804
  22. Dragovic J, Doyle TJ, Tilchen EJ, et al.  Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer. Cancer. 1995;1:1655–1661

PII: S0196-0709(02)32409-8

doi: 10.1053/ajot.2003.7

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 24, Issue 1 , Pages 1-5 , January 2003

Article Tools